Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA, Young HS, Tyrrell DL, Vederas JC, Lemieux MJ. · 2020
Read Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. by Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA, Young HS, Tyrrell DL, Vederas JC, Lemieux MJ. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7453019.txt.
Description
Vuong and co-authors test a cat coronavirus drug against the main protease of SARS-CoV-2. The protease cuts the virus's long protein chain into working parts. Blocking it should stop the virus from copying itself.
The prodrug GC376 had cured a fatal coronavirus disease in cats. Its parent form is GC373. Both blocked the protease of SARS-CoV and SARS-CoV-2 at very low doses in lab tests. Crystal images show the drugs bound to the active site of the enzyme. Nuclear magnetic checks show the block can reverse. Both drugs also stopped SARS-CoV-2 growth in cell culture. Since they already worked in animals, the authors back them as candidates for human trials.
Catalog record
| CREATOR | Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA, Young HS, Tyrrell DL, Vederas JC, Lemieux MJ. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |